Lung Cancer

ctDNA detects actionable mutations in advanced NSCLC: Australian results

Queensland research is advancing ctDNA testing as a tool to detect clinically actionable mutations in blood samples from patients with NSCLC. The cross-sectional study applied the UltraSEEK lung panel (Agena Bioscience), which detects 73 clinically relevant variants across BRAF, EGFR, ERBB2, KRAS and PIK3CA genes, to samples from 103 patients with advanced NSCLC undergoing systemic ...

Already a member?

Login to keep reading.

© 2022 the limbic